[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor
[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor
Clinical study to demonstrate an at least equivalent performance of a new PET molecular
 Imaging radiopharmaceutical named [18F] LBT-999 in brain imaging compared to the SPECT
 reference method named [123I]-FP-CIT to establish the differential diagnosis between
 Parkinson's Disease and Essential Tremor.
Inclusion Criteria:

 -  Patient:

 -  suffering from an essential tremor according to the 2000 criteria of Elble
 (excluding head's tremor)

 -  or with Parkinson's disease according to UKPDSBB criteria

 -  Patient whose diagnosis is more than 18 months old

 -  Patient affiliated with a health protection system or beneficiary of such a system

 -  Patient who has received complete information on the organization of the research and
 signed his informed consent

 Exclusion Criteria:

 -  Patient with atypical non-idiopathic parkinsonian syndrome

 -  Patient treated with deep brain stimulation

 -  Patient suffering from abnormal functional psychogenic movements

 -  Patient with severe and progressive psychiatric disorders

 -  Patient with disabling dyskinesia or essential tremor, incompatible with performing
 imaging exams

 -  Patient who had an ionizing examination at the cerebral level less than 3 months old

 -  Person with a contraindication to performing PET or SPECT imaging:

 -  Patient with claustrophobia

 -  Patient refusing to be informed in case of abnormalities detected during imaging
 examinations

 -  Patients treated with amphetamines, benzatropine, amfebutamone, cocaine,
 mazindol, methylphenidate, phentermine or sertraline

 -  Person with a known allergy to the active substance or to any of the excipients
 of the evaluated product or reference product or to potassium iodide

 -  A woman of childbearing potential who does not have effective contraception according
 to investigator judgment

 -  Patient unable to sign the informed consent

 -  Patient participating to a protocol or period of exclusion from a protocol

 -  Patient who received benefits over € 4,500 in the last 12 months prior to inclusion in
 clinical studies

 -  Patient in exclusion period in national volunteer file during which he can not
 participate in another clinical study

 -  Patient not affiliated to a health protection system

 -  Patient refusing to participate

 -  Persons referred to in Articles L. 1121-5 to L. 1121-8 and L1122-2 of the French
 Public Health Code:

 -  Pregnant or lactating woman

 -  Person deprived of liberty by a judicial or administrative decision,

 -  Person under psychiatric care

 -  Person admitted to a health or social institution for purposes other than
 research

 -  Person who is the subject of a legal protection measure (tutelage, guardianship,
 safeguard of justice)

 -  Major person unable to express consent and who is not subject to a legal
 protection measure